Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
2 evidence topics · 5 sources
Summary
Current care includes trigger avoidance, symptom-directed medicines, anaphylaxis preparedness, and treatment of skeletal complications. Avapritinib is FDA approved for adults with ISM. SUMMIT nevertheless enrolled participants with inadequate symptom control despite at least two anti-mediator therapies. The available evidence therefore describes a population with persistent symptoms on existing care; it does not establish that all treated people with nonadvanced SM require a KIT inhibitor. The effect of KIT inhibition on disease progression is not established.